Lisata Therapeutics, Inc.

As of February 27, 2025, Lisata Therapeutics, Inc. is rated "risky" and considered overvalued, with a year-to-date return of -19.80%, significantly underperforming the S&P 500's 2.44% return.

As of May 12, 2025, Lisata Therapeutics, Inc. shows a mildly bearish trend driven by daily moving averages, despite some mildly bullish signals from the weekly MACD and KST, indicating overall weakness in momentum.

As of March 2022, the management team of Lisata Therapeutics, Inc. includes Dr. Gregory Brown (Independent Chairman), Dr. David Mazzo (CEO), Dr. Michael Davidson, Ms. Anne Whitaker, and independent directors Mr. Steven Klosk, Mr. Steven Myers, and Ms. Cynthia Schwalm. They are responsible for the company's strategic direction and operations.

Lisata Therapeutics, Inc. is a biopharmaceutical company focused on developing cell therapies for cardiovascular and autoimmune diseases. It has a market cap of $20.66 million and reported a net profit loss of $5 million as of March 2025.

As of Jun 18, Lisata Therapeutics, Inc. has a market capitalization of 20.66 million, with net sales of 1.00 million and a net loss of 19.30 million over the latest four quarters. Shareholder's funds are valued at 29.57 million, and total assets amount to 35.00 million.